Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Drug List Coverage & PA Policy | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    EmblemHealth 2026 Drug List (Large Group Generic Formulary) — Coverage Criteria

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the covered prescription drugs, tiers, and utilization management (e.g., prior authorization, quantity limits, step therapy) for EmblemHealth large group plans; affects members, prescribing providers, and pharmacies using the plan's drug list.

    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth 2026 Drug List (Large Group Generic Formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and document quantity limits/specialty routing for drugs flagged PA, QL, or SP before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    LGENDrug List ID
    2026-01-01Effective
    TieredTiering
    MultiplePA flagged (excerpt)
    SomeQL noted
    877-793-6253Pharmacy CS

    Coverage Criteria and Formulary Controls

    General formulary coverage and utilization controls

    Coverage with administrative controls

    Formulary coverage rules: Drugs listed are on the formulary with a specified Drug Tier; many have Requirements/Limits such as PA (prior authorization), QL (quantity limit), SP (specialty), LA (limited access), or ACA (ACA-mandated coverage). Providers must obtain required authorizations where indicated.

    This section lists drugs and their administrative flags; clinical necessity criteria are handled via PA processes referenced by these flags.

    Specialty/PAH agent coverage

    Covered with prior authorization and quantity limits for specific specialty/PAH agents when PA obtained

    PA-required specialty agents: Agents such as ambrisentan, bosentan, ivabradine, sildenafil (Revatio), and tadalafil (Adcirca) require prior authorization and have specified quantity limits (see QL entries).PA + specified QL
    Policy Summary
    PayerEmblemHealth
    PolicyEmblemHealth 2026 Drug List (Large Group Generic Formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and document quantity limits/specialty routing for drugs flagged PA, QL, or SP before dispensing.
    SourceLink
    On This Page
    Coverage Criteria and Formulary ControlsFormulary Entries and Code TablesProvider Responsibilities: Authorization, Documentation, and DispensingQuantity Limits (QL) — Examples and ValuesSpecialty Pharmacy and Dispensing RequirementsStep Therapy and Related FlagsDefinitions and AcronymsBackground

    LA or SP noted for some products

    Standard formulary agents

    Formulary-listed common cardiovascular and antihypertensive agents

    Formulary oral cardiovascular agents: Wide list of beta blockers, ACE inhibitors, ARBs, calcium channel blockers, diuretics, antiarrhythmics, and antihyperlipidemics are listed with Drug Tier = 1; most have no additional limits noted in these chunks.none

    Some specific formulations (e.g., enalapril oral solution) have PA/QL

    General coverage stance

    Coverage is product-specific with utilization controls applied where noted

    Formulary coverage with controls: Drug entries are covered on the formulary at the indicated drug tier when dispensing follows any associated controls (QL, PA, SP).see individual product QL/PA/SP annotations

    Authorizations required when PA is present.

    Formulary coverage with product-specific controls

    Coverage and utilization controls as listed per product

    Formulary inclusion: Drugs listed are included on the EmblemHealth formulary with an assigned Drug Tier and may have Requirements/Limits such as QL (quantity limits), PA (prior authorization), SP (specialty), ACA (ACA-mandated coverage), or ST (step therapy).

    Each product line has individualized controls as shown in the formulary entries.

    Formulary entries with authorization and quantity rules

    Coverage entries for listed drugs (examples):

    Eltrombopag (Promacta): Eltrombopag products listed with Drug Tier = 1 and Requirements/Limits = PA, QL (30 or 60 tablets/30 days depending on strength), SP.QL 30 or 60 tablets/30 days

    chunks 164-165

    Glutamine (Endari): Glutamine powder pack 5 gm (Endari) listed with Drug Tier = 1 and Requirements/Limits = PA, SP.

    chunk 165

    Miglustat (Zavesca): Miglustat cap 100 mg listed with Drug Tier = 1 and Requirements/Limits = LA, PA, QL (90 capsules/30 days), SP.QL 90 capsules/30 days

    chunk 166

    Icatibant (Firazyr): Icatibant acetate subcutaneous pref syringe 30 mg/3 ml listed with Drug Tier = 1 and Requirements/Limits = LA, PA, QL (6 syringes/30 days), SP.QL 6 syringes/30 days

    chunk 169

    Enoxaparin (Lovenox): Enoxaparin prefilled syringes and vials listed with QL limits (30 syringes/90 days; 10 vials/90 days).QL as stated

    chunks 166-167

    Rivaroxaban (Xarelto): Rivaroxaban suspension and tablets listed with QL (620 mls/30 days for suspension; 60 tablets/30 days for 2.5 mg).QL as stated

    chunks 167-168

    Latanoprost (Xalatan): Latanoprost ophthalmic solution 0.005% listed with QL (2.5 mls/30 days).2.5 mls/30 days

    chunk 171

    Formulary coverage and constraints

    Covered when listed on formulary with stated tier and requirements/limits

    Formulary coverage: Drugs listed are covered under the pharmacy benefit with the Drug Tier indicated; coverage is subject to any Requirements/Limits (e.g., QL, PA, SP, ACA). Specific medical necessity criteria are implemented via individual PA processes where flagged.

    This part enumerates items and their constraints; consult product entries for exact QL/PA/SP requirements.

    Please consult the member's Certificate of Coverage for plan-specific benefits and cost-sharing. Not all drugs listed are paid for by all drug benefit plans; listing on the formulary does not guarantee coverage for every plan or member. The Certificate of Coverage and member ID card contact information identify any plan-specific coverage restrictions and how to request further information.

    Within the provided formulary excerpt there are no explicit clinical exclusion statements. Entries instead use administrative flags (e.g., PA, QL, SP, LA, ACA) to indicate utilization controls that affect coverage and access rather than categorical clinical exclusions.

    Restrictions in this segment are expressed as administrative designations such as PA (prior authorization), QL (quantity limit), LA (limited access), and SP (specialty). The document does not list therapeutic exclusions here; instead, these requirement codes limit coverage or specify dispensing/authorization workflows for particular agents.

    Products annotated with ACA (Affordable Care Act) in the formulary—notably contraceptive products and related items—indicate coverage consistent with ACA preventive services requirements rather than exclusion. These ACA-marked contraceptives are therefore represented as mandated coverage under the plan's preventive benefits.

    Many formulary entries show blank or no Requirements/Limits fields in this excerpt. A blank Requirements/Limits entry implies standard formulary coverage without a listed prior authorization, quantity limit, specialty routing, or other special administrative constraint in the excerpted segment.

    Items designated PA or SP require prior authorization or specialty pharmacy routing before the plan will cover or dispense the product. These designations limit coverage at point of dispensing unless the required authorization or specialty process has been completed.

    Within these chunks there are no explicit therapeutic exclusions; the listing is a formulary enumeration. Some items carry administrative designations (e.g., PA, SP) or quantity limits that condition coverage, but no products are expressly listed as excluded in the provided text.

    Review of this segment found no statements declaring products Not Medically Necessary. The excerpt is primarily an index/product listing and does not include any explicit "Not Medically Necessary" determinations in the cited text.

    Formulary Entries and Code Tables

    Selected Covered Drugs (from Penicillins section)mixedCovered
    amoxicillin (trihydrate) cap 250 mg, 500 mgamoxicillin capsules 250 mg and 500 mg
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlamoxicillin oral suspension various strengths
    amoxicillin (trihydrate) tab 500 mg, 875 mgamoxicillin tablets 500 mg and 875 mg
    amoxicillin & k clavulanate for susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5mlamoxicillin-clavulanate oral suspension strengths
    amoxicillin & k clavulanate for susp 600-42.9 mg/5ml (Augmentin es-600)amoxicillin-clavulanate suspension 600-42.9 mg/5ml (Augmentin ES-600)
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgamoxicillin-clavulanate tablets multiple strengths
    ampicillin cap 500 mgampicillin capsules 500 mg
    dicloxacillin sodium cap 250 mg, 500 mgdicloxacillin capsules 250 mg and 500 mg
    Formulary drug items in excerpt (by name/presentation)mixed
    amoxicillin (trihydrate) cap 250 mg, 500 mgamoxicillin (trihydrate) cap 250 mg, 500 mg
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlamoxicillin (trihydrate) for suspension
    amoxicillin & k clavulanate for susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5mlamoxicillin-clavulanate suspensions
    amoxicillin & k clavulanate for susp 600-42.9 mg/5ml (Augmentin es-600)Augmentin ES-600 suspension
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgamoxicillin-clavulanate tablets
    cefadroxil cap 500 mgcefadroxil 500 mg capsules
    cephalexin cap 250 mg, 500 mg, 750 mgcephalexin capsules
    azithromycin for susp 100 mg/5ml, 200 mg/5ml (Zithromax)azithromycin suspensions
    clarithromycin tab er 24hr 500 mgclarithromycin ER 500 mg
    doxycycline hyclate cap 50 mg, 100 mgdoxycycline hyclate capsules
    1–10 of 22
    1/3
    Formulary requirement flagsmixed
    ACAAffordable Care Act required coverage/limits flag as listed in Requirements/Limits
    PAPrior Authorization required
    QLQuantity Limit
    SPSpecialty pharmacy or specialty handling
    Formulary drug list (no billing codes)mixed
    NDC/HCPCS not providedDocument lists drug names and strengths; no explicit billing codes provided in this section.
    Selected listed products and constraintsmixed
    tolvaptan tab 30 mgSamsca; QL (30 tablets/365 days) and also listed with QL (60 tablets/365 days)
    digoxin oral soln 0.05 mg/mlDigoxin; Drug Tier = 1; Requirements/Limits = PA
    digoxin tab 62.5 mcg, 125 mcg, 250 mcgLanoxin; Drug Tier = 1
    Cardiovascular agents (beta blockers, antianginal)mixedCovered
    nitroglycerin sl tab 0.3/0.4/0.6 mgNitrostat
    ranolazine tab er 500 mg, 1000 mgRanexa
    carvedilol tab 3.125-25 mgCoreg
    Diuretics and vasopressorsmixedCovered
    furosemide tab 20/40/80 mgLasix
    spironolactone tab 25/50/100 mgAldactone
    epinephrine auto-injector 0.15 mg / 0.3 mgEpiPen-jr / EpiPen (listed under vasopressors)
    Pulmonary hypertension / specialty cardiovascular agentsmixed
    ambrisentan tab 5 mg, 10 mgLetairis — LA, PA, QL (30 tablets/30 days), SP
    bosentan tab 62.5 mg, 125 mgTracleer — PA, QL (60 tablets/30 days), SP
    ivabradine tab 5 mg, 7.5 mgCorlanor — PA, QL (60 tablets/30 days)
    sildenafil citrate tab 20 mg (Revatio)PA, QL (90 tablets/30 days), SP
    tadalafil tab 20 mg (Adcirca)PA, QL (60 tablets/30 days), SP
    sacubitril-valsartan tab 24-26 / 49-51 / 97-103 mgEntresto
    AntihyperlipidemicsmixedCovered
    ezetimibe tab 10 mgZetia
    fenofibrate cap/tabTricor / other fenofibrate formulations
    statins (atorvastatin, simvastatin, rosuvastatin, pravastatin, etc.)Multiple listed strengths; some entries marked 'ACA'
    Formulary drug entries (product lines)mixedCovered
    EndometrinEndometrin — Requirements/Limits = QL (84 suppositories/28 days)
    terconazole vaginal cream 0.4%, 0.8%Drug Tier = 1
    terconazole vaginal suppos 80 mgDrug Tier = 1
    TODAY SPONGE - nonoxynol-9 vaginal sponge 1000 mgDrug Tier = 1; Requirements/Limits = ACA
    VCF VAGINAL CONTRACEPTIVE - nonoxynol-9 foam 12.5%Drug Tier = 1; Requirements/Limits = ACA
    VCF VAGINAL CONTRACEPTIVE - nonoxynol-9 film 28%Drug Tier = 1; Requirements/Limits = ACA
    VCF VAGINAL CONTRACEPTIVE - nonoxynol-9 gel 4%Drug Tier = 1; Requirements/Limits = ACA
    alfuzosin hcl tab er 24hr 10 mg (Uroxatral)Drug Tier = 1
    dutasteride cap 0.5 mg (Avodart)Drug Tier = 1
    finasteride tab 5 mg (Proscar)Drug Tier = 1
    1–10 of 23
    1/3
    Formulary drug entries (sample)mixedCovered
    atomoxetine hcl cap 10 mg, 18 mg, 25 mg, 40 mgDrug Tier = 1; QL (60 capsules/30 days)
    atomoxetine hcl cap 60 mg, 80 mg, 100 mgDrug Tier = 1; QL (30 capsules/30 days)
    caffeine citrate oral soln 60 mg/3mlDrug Tier = 1
    clonidine hcl tab er 12hr 0.1 mgDrug Tier = 1; QL (120 tablets/30 days)
    dexmethylphenidate hcl cap er 24 hr (Focalin XR) 5-40 mgDrug Tier = 1; QL (30 capsules/30 days)
    dexmethylphenidate hcl tab (Focalin) 2.5-10 mgDrug Tier = 1; QL (60 tablets/30 days)
    dextroamphetamine sulfate (Dexedrine) various formulationsDrug Tier = 1; QL values vary by formulation
    guanfacine hcl tab er 24hr (Intuniv) 1-4 mgDrug Tier = 1; QL (30 tablets/30 days)
    liraglutide (Saxenda) soln pen-inj 18 mg/3mlDrug Tier = 1*; PA, QL (15 mls/30 days)
    lisdexamfetamine dimesylate (Vyvanse) caps/chew tabs 10-70 mgDrug Tier = 1; QL (30 units/30 days)
    1–10 of 20
    1/2
    Quantity limits examplesmixed
    enoxaparin prefilled syringes QLQL for enoxaparin prefilled syringes (Lovenox) noted as QL (30 syringes/90 days) and enoxaparin vials QL (10 vials/90 days)
    Ophthalmic QLmixed
    latanoprost (Xalatan) QLQL for latanoprost ophthalmic solution (Xalatan) 2.5 mls/30 days
    Formulary drug listings (partial)mixed
    erythromycin soln 2%erythromycin soln 2%
    fluocinolone acetonide cream 0.01%fluocinolone acetonide cream 0.01% — QL (120 grams/30 days)
    fluocinonide cream 0.1% (Vanos)fluocinonide cream 0.1% (Vanos) — QL (240 grams/28 days)
    lidocaine patch 5% (Lidoderm)lidocaine patch 5% — Requirements/Limits = PA, QL (90 patches/30 days)
    tazarotene cream/geltazarotene formulations — some Requirements/Limits = PA
    lenalidomide caps (Revlimid)lenalidomide — Requirements/Limits = PA, QL (30 capsules/30 days or 21 capsules/28 days), SP
    Indexed drug entriesmixed
    anagrelide hcl cap 0.5 mglisted as index entry
    anagrelide hcl cap 1 mglisted as index entry
    anastrozole tab 1 mglisted as index entry
    apomorphine hcl soln cartridge 30 mg/3mllisted as index entry
    aprepitant capsule 80 mglisted as index entry
    APRETUDElisted brand entry
    Indexed drug entries (continued)mixed
    azithromycin tab 250 mglisted as index entry
    azithromycin tab 500 mglisted as index entry
    azithromycin tab 600 mglisted as index entry
    Formulary drug list (excerpts)mixed
    buspirone hcl tab 5 mg, 10 mg, 15 mg, 30 mglisted formulation and strengths
    bupropion hcl tab 75 mglisted
    bupropion hcl tab 100 mglisted
    bupropion hcl tab er 12hr 100 mglisted
    bupropion hcl tab er 12hr 150 mglisted
    bupropion hcl tab er 24hr 150 mglisted
    bupropion hcl tab er 24hr 300 mglisted
    butalbital-acetaminophen-caffeine tab 50-325-40 mglisted
    buprenorphine hcl sl tab 2 mg, 8 mg (base equiv)listed
    buprenorphine hcl-naloxone hcl sl tab 2-0.5 mg, 8-2 mg (base equiv)listed
    1–10 of 22
    1/3
    Formulary product entriesmixed
    butalbital-acetaminophen tab 50-325 mglisted product and strength
    butalbital-aspirin-caffeine cap 50-325-40 mglisted product and strength
    butalbital-aspirin-caff w/ codeine cap 50-325-40-30 mglisted product and strength
    butorphanol tartrate nasal soln 10 mg/mllisted product and strength
    Formulary product entries continuedmixed
    cefadroxil cap 500 mglisted product and strength
    cefdinir cap 300 mglisted product and strength
    cefixime cap 400 mglisted product and strength
    celecoxib cap 50 mg, 100 mg, 200 mg, 400 mglisted product and strengths
    cephalexin cap 250 mg, 500 mg, 750 mglisted product and strengths
    Topicals, injectables, and other productsmixed
    clindamycin hcl cap 75 mg, 150 mg, 300 mglisted product and strengths
    clobetasol propionate cream/foam/gel/oint 0.05%listed topical formulations and strength
    cyanocobalamin inj 1000 mcg/mllisted injectable formulation
    Selected systemics and topicalsmixed
    dexamethasone tab 0.5 mg - 6 mgoral tablet strengths listed
    diazepam tab 2 mg, 5 mg, 10 mglisted product and strengths
    diclofenac sodium (actinic keratoses) gel 3%topical product and strength
    Antivirals, injectables, hormonesmixed
    darunavir tab 600 mg, 800 mgantiretroviral strengths listed
    efavirenz-emtricitabine-tenofovir df tab 600-200-300 mgcombination antiretroviral
    enoxaparin sodium inj soln pref syr various strengthslisted LMWH prefilled syringes
    estradiol td patch and gels various strengthshormone therapy products listed
    Quantity limits called out (examples)
    Tolvalptan (Samsca/JYNARQUE)Examples include QL 30 tablets/365 days (Samsca 30 mg) and QL 56 tablets/28 days (JYNARQUE therapy pack) and related LA/PA/SP controls
    Pulmonary hypertension agentsExamples include QL 30 tablets/30 days (ambrisentan) and QL 60 tablets/30 days (bosentan)
    PAH PDE5 agentsExamples include QL 90 tablets/30 days (sildenafil Revatio) and QL 60 tablets/30 days (tadalafil Adcirca)
    Selected Quantity Limits
    Endometrin (progesterone vaginal insert)QL 84 suppositories/28 days
    Aripiprazole oral solution 1 mg/mLQL 900 mls/30 days
    Clozapine (selected tab strengths)QL varies by strength (90–270 tablets/30 days)
    Tasimelteon (Hetlioz) 20 mgPA; QL 30 capsules/30 days; SP
    Liraglutide (Saxenda)PA; QL 15 mls/30 days
    Quantity limits examples (Concerta, oxycodone soln, tramadol ER)
    Concerta (methylphenidate ER osmotic)QL 30 tablets/30 days (some strengths 60 tablets/30 days)
    Oxycodone HCl solution 5 mg/5 mLQL 5400 mls/30 days
    Tramadol HCl ER 100 mgPA; QL 30 tablets/30 days
    Quantity limits examples (various measures)
    Topical corticosteroids (examples)QL examples: fluocinolone acetonide cream 0.01% QL 120 grams/30 days; fluocinonide cream 0.1% (Vanos) QL 240 grams/28 days
    Lidocaine topical productsPA; QL examples: lidocaine solution 4% QL 150 mls/30 days; lidocaine oint 5% QL 100 grams/30 days; lidocaine patch 5% QL 90 patches/30 days
    Triamcinolone preparationsQL 454 grams/30 days (various forms)
    Lenalidomide (Revlimid)PA, SP; QL 30 capsules/30 days or 21 capsules/28 days depending on strength

    Provider Responsibilities: Authorization, Documentation, and Dispensing

    Prior Authorization

    Obtain Prior Authorization for PA‑flagged drugs

    Some drugs listed on the formulary require prior authorization (PA). Prescribers must obtain plan approval before dispensing those products or coverage may be denied.

    • PA is indicated by the 'PA' flag next to product listings and defined in the abbreviations section.
    Prior Authorization

    PA required for select antifungals

    Certain antifungal products (for example, posaconazole suspension and voriconazole formulations) are marked PA and require prior authorization before the plan will pay.

    • Posaconazole susp 40 mg/mL (Noxafil) — Requirements/Limits = PA.
    • Voriconazole for suspension and tablet strengths — Requirements/Limits = PA.
    Prior Authorization

    PA required for many antineoplastics/specialty oncolytics

    Many antineoplastic and specialty oral oncology agents are designated PA (and often QL and SP); prescribers must secure prior authorization for these agents before coverage.

    • Examples include abiraterone, dasatinib, erlotinib, everolimus, imatinib and other oncology agents listed with PA, QL, SP.
    Prior Authorization

    Obtain PA for selected specialty/limited‑access agents

    Drugs marked with Requirements/Limits such as PA, LA, QL, or SP (examples: JYNARQUE/tolvaptan, sapropterin/Kuvan, carglumic acid/Carbaglu, teriparatide) require prior authorization before coverage is allowed.

    • JYNARQUE (tolvaptan) — Requirements/Limits = LA, PA, QL, SP.
    • Sapropterin (Kuvan) and carglumic acid (Carbaglu) — listed with LA/PA/SP where noted.
    Prior Authorization

    Secure PA for select PAH and specialty cardiovascular agents

    Several pulmonary hypertension (PAH) agents (ambrisentan, bosentan) and related specialty cardiovascular agents (ivabradine, sildenafil, tadalafil) carry PA and specified quantity limits; prior authorization must be obtained.

    • Ambrisentan (Letairis) — Requirements/Limits = LA, PA, QL (30 tablets/30 days), SP.
    • Bosentan (Tracleer) — Requirements/Limits = PA, QL (60 tablets/30 days), SP.
    • Ivabradine (Corlanor), sildenafil (Revatio), tadalafil (Adcirca) — PA with stated QLs.
    Prior Authorization

    PA required for assorted listed drugs (examples)

    Many formulary products include Requirements/Limits annotations indicating PA is required for coverage; prescribers must obtain PA for those examples shown in the listing.

    • Examples across sections include pirfenidone (Esbriet), famotidine suspensions, glycopyrrolate, and various renal/gastro products listed with PA.
    Prior Authorization

    PA required for select topicals (lidocaine, retinoids) and others

    Certain topical and other non‑systemic products (e.g., lidocaine topical solutions/ointments/patches and some topical retinoids) are listed with PA and QL; prescribers must obtain authorization when indicated.

    • Lidocaine hcl solution 4%/ointment 5%/patch 5% — Requirements/Limits = PA, QL (150 mL / 100 g / 90 patches per 30 days respectively).
    • Tazarotene and tretinoin formulations — Requirements/Limits = PA for some formulations.
    Prior Authorization

    PA required for weight‑management and controlled products

    Weight‑management and certain controlled appetite suppressants (liraglutide/Saxenda, phentermine products, phentermine‑topiramate/Qsymia) are marked PA (and have QL); prescribers must obtain prior authorization.

    • Liraglutide (Saxenda) — Requirements/Limits = PA, QL (15 mL/30 days).
    • Phentermine and phentermine‑topiramate (Qsymia) — Requirements/Limits = PA and QL as listed.
    Prior Authorization

    PA required for select hematologic and specialty agents

    Selected listed specialty or hematologic drugs require prior authorization and may be routed via specialty pharmacy; examples include eltrombopag (Promacta), glutamine (Endari), and miglustat (Zavesca).

    • Eltrombopag — Requirements/Limits = PA, QL (30 or 60 tablets/30 days depending on strength), SP.
    • Endari (glutamine) — Requirements/Limits = PA, SP; Miglustat (Zavesca) — Requirements/Limits = LA, PA, QL (90 capsules/30 days), SP.
    Prior Authorization

    PA required for select topical/specialty products (lenalidomide example)

    Prescribers must obtain prior authorization for certain topical and specialty oncology products (lenalidomide/Revlimid is listed with PA, QL and SP); coverage requires PA and specialty dispensing compliance.

    • Lenalidomide (Revlimid) — Requirements/Limits = PA, QL (30 capsules/30 days or 21 capsules/28 days depending on strength), SP.
    Note

    Index segment — no PA rules

    No prior authorization rules are specified in this index segment.

    Note

    Index — PA not listed

    This index segment does not list prior authorization requirements.

    Note

    No PA specified in this segment

    This segment enumerates drug names and strengths and does not specify prior authorization requirements.

    Note

    PA not specified in index portion

    This portion of the listing does not identify prior authorization requirements; it is a formulary product index.

    Step Therapy

    Follow Step Therapy (ST) requirements where annotated

    Some products are subject to step therapy (ST); the plan may require trying specified drugs first before covering alternatives — prescribers should follow ST edits where present.

    • ST is defined in the abbreviations and used for agents such as Gralise (once‑daily gabapentin formulations) which are marked ST.
    Note

    Observe administrative modifiers (ACA, LA, SP)

    Entries include modifiers such as ACA, LA, and SP which denote special coverage categories or site/plan constraints; prescribers should interpret these flags per the abbreviations and plan guidance.

    • ACA indicates Affordable Care Act preventive coverage rules; LA indicates limited availability; SP indicates specialty drug handling.
    Documentation Required

    Provide documentation for PA requests (per chunk 36 flags)

    Prescribers should provide supporting documentation when prior authorization is requested for products flagged in the formulary (examples flagged in chunk 36).

    • Documentation may be requested to support PA decisions for specialty vaccines, biologics, or agents listed with PA/SP.
    Step Therapy

    Step/specialty program applies for some specialty agents

    Some specialty agents are subject to step or specialty program requirements; prescribers must follow specialty program enrollment and authorization rules when SP/LA is indicated.

    • Examples include octreotide, sapropterin, sodium phenylbutyrate, and tolvaptan variants which are marked SP or LA and require program management.
    Documentation Required

    Submit required documentation with PA/QL requests

    Prescriptions for products marked PA or QL require documentation and adherence to the formulary's PA/QL procedures; pharmacies and prescribers must follow the payer's documentation process when submitting requests.

    • PA and QL notations (e.g., lidocaine PA/QL, lenalidomide PA/QL/SP) require submission of supporting information as part of the authorization.
    Note

    No explicit step therapy sequences — follow PA/QL/SP flags

    Many entries show PA/QL/SP flags but no explicit step therapy algorithm is provided in these chunks; prescribers should follow PA and QL rules even where ST sequence is not specified.

    • PA, QL and SP flags indicate utilization controls even if detailed step sequences are absent.
    Note

    Index entries — follow PA/QL/SP where noted

    This index segment primarily contains tier, QL, PA and SP annotations without explicit step therapy sequences; prescribers must comply with those utilization controls.

    Step Therapy

    Adhere to ST for agents marked ST (e.g., Gralise)

    Some products are explicitly marked ST (step therapy), for example Gralise (once‑daily gabapentin formulations); prescribers must meet step requirements before coverage is allowed.

    • Gralise formulations — Requirements/Limits include ST and specified QLs.
    Documentation Required

    Provide supporting clinical documentation for specialty PA requests

    Prescribers must provide documentation supporting PA when requested for specialty products such as eltrombopag, glutamine (Endari), miglustat (Zavesca), and icatibant (Firazyr).

    • Eltrombopag, Endari, Miglustat, Icatibant — listed with PA and SP/LA designations that require supporting clinical documentation.
    Note

    Step therapy not detailed — follow PA/QL annotations

    No explicit step therapy algorithms are listed in these chunks; where ST is absent, follow PA and QL rules indicated for each product.

    Note

    No step therapy requirements in this index segment

    This index portion does not show step therapy requirements; it is a product listing — rely on PA/QL/SP flags for utilization controls.

    Documentation Required

    Follow formulary PA/QL/SP and documentation for index entries (chunk 216)

    This provider actions placeholder references items flagged in chunk 216; prescribers should follow PA/QL/SP and documentation instructions found in the formulary when managing these listed products.

    Documentation Required

    Follow PA/QL/SP for entries referenced in chunk 244

    This provider actions placeholder references items flagged in chunk 244; ensure PA/QL/SP requirements are met when prescribing the products shown in that index listing.

    Documentation Required

    Comply with PA/QL/SP for indexed products (chunk 263)

    This provider actions placeholder references items flagged in chunk 263; for those indexed products, comply with any PA, QL or specialty routing requirements indicated in the formulary.

    Note

    Check the member's Certificate of Coverage

    Members should consult their Certificate of Coverage for plan‑specific benefit details, including whether a listed drug is covered under their particular drug benefit plan.

    • Certificate of Coverage will specify coverage and member cost‑sharing; not all drugs in the list are paid for by every plan.
    Documentation Required

    Document QL for select antivirals on PA submissions

    Several antiviral oral solutions and suspensions include quantity limits; prescribers must document quantities on PA requests when applicable (examples: abacavir and lamivudine oral solutions QL 960 mL/30 days).

    • Abacavir oral solution 20 mg/mL — QL 960 mL/30 days.
    • Lamivudine oral solution 10 mg/mL — QL 960 mL/30 days.
    Note

    Interpret Requirements/Limits flags (ACA, PA, QL, SP)

    Interpret 'ACA', 'PA', 'QL', and 'SP' flags per the abbreviations: ACA = ACA preventive coverage, PA = prior authorization required, QL = quantity limit, SP = specialty pharmacy designation.

    Documentation Required

    Provide required documentation for PA/QL requests

    Prescribers must follow payer prior authorization and quantity‑limit requirements for drugs marked PA, LA, QL, or SP; submit clinical justification and documentation as requested.

    • PA/QL/SP annotations on product lines indicate the need for authorization and supporting documentation.
    Documentation Required

    Document PA and QL for enalapril oral solution (Epaned)

    Enalapril maleate oral solution (Epaned) is designated PA with a quantity limit of 1200 mL per 30 days; prescribers must document PA and QL adherence when requesting coverage.

    • Enalapril oral solution 1 mg/mL (Epaned) — Requirements/Limits = PA, QL (1200 mL/30 days).
    Documentation Required

    Document suspensions/packets on PA requests

    Some oral suspensions and packet formulations (e.g., famotidine suspension, esomeprazole packets) have PA and/or QL; include supporting prescription and diagnosis documentation when submitting PA.

    • Esomeprazole delayed‑release suspension packets — QL (60 packets/30 days).
    • Famotidine suspension 40 mg/5 mL — Requirements/Limits = PA, QL (2400 mL/30 days).
    Billing Rule

    Obtain PA and follow specialty dispensing rules for PA/QL/SP products

    Products marked PA or PA, QL, SP require the prescriber or pharmacy to obtain prior authorization and to follow specialty dispensing rules where SP is indicated.

    • Tasimelteon (Hetlioz) — Requirements/Limits = PA, QL (30 capsules/30 days), SP.
    • Liraglutide (Saxenda) — Requirements/Limits = PA, QL (15 mL/30 days).
    Billing Rule

    Route SP‑designated drugs through specialty pharmacy

    Products designated SP should be dispensed via specialty pharmacy channels as indicated by the formulary; prescribers and pharmacies must route fills accordingly.

    • Examples include Tecfidera, Copaxone, Gilenya and other SP‑flagged agents.
    Documentation Required

    Be prepared to submit clinical documentation with PA

    When prior authorization is requested, prescribers must be prepared to provide clinical supporting documentation as requested by the payer for products marked PA.

    • Supporting clinical information may be required for approval of specialty or PA‑flagged agents (e.g., eltrombopag, Endari, miglustat, icatibant).
    Documentation Required

    Document quantity limits when submitting PA/QL requests

    PA and QL annotations require documentation per formulary policy; prescribers should include quantity justification when requesting coverage for QL‑limited products.

    • Quantity limits (e.g., lidocaine solution 150 mL/30 days, lidocaine patch 90 patches/30 days) must be documented to support dispenses.
    Note

    Index segment — see product listings for authorization rules

    This index segment provides names and page references only and does not include authorization requirements; consult the product listing pages for PA/QL/SP flags.

    Documentation Required

    Follow PA/QL/SP and documentation for entries in chunk 216

    This provider actions placeholder references items flagged in chunk 216—follow the formulary's PA/QL/SP and documentation guidance for those listed products.

    Documentation Required

    Comply with PA/QL/SP for entries in chunk 234

    This provider actions placeholder references items flagged in chunk 234—ensure PA/QL/SP requirements are met and documentation submitted as required by the payer for those products.

    Documentation Required

    Follow PA/QL/SP for products indexed in chunk 258

    This provider actions placeholder references items flagged in chunk 258—prescribers and pharmacies must follow PA, QL and specialty routing rules for those indexed products.

    Denial Risk

    Denial risk if PA not obtained

    Failure to obtain required prior authorization (PA) may result in the plan not covering the drug; prescribers should obtain PA prior to dispensing PA‑flagged products.

    • If approval is not obtained, the plan may deny coverage at point of service.
    Denial Risk

    Denial risk for antifungals without PA

    If a product flagged PA is dispensed without prior authorization (for example posaconazole or voriconazole), the claim may be denied; obtain PA to avoid non‑coverage.

    Denial Risk

    PA risk for oncology/specialty agents

    Coverage for listed PA items (notably antineoplastics and specialty oncology agents) is subject to prior authorization; failure to secure PA can result in coverage denial or limits.

    Denial Risk

    Denial risk when PA/LA/QL/SP criteria not met

    Products with Requirements/Limits (PA, LA, QL, SP) such as JYNARQUE, Kuvan, Carbaglu and teriparatide will require approval processes and may be denied if criteria or documentation are not met.

    Denial Risk

    PA/QL enforcement may trigger denial

    PA and quantity‑limit enforcement applies to selected agents (e.g., ambrisentan, bosentan, ivabradine, sildenafil/tadalafil for PAH); claims may be denied if PA is missing or QL exceeded.

    • Ivabradine (Corlanor) — PA, QL (60 tablets/30 days); sildenafil (Revatio) and tadalafil (Adcirca) — PA with stated QLs.
    Denial Risk

    Ivabradine (Corlanor) — PA and QL denial risk

    Requests for ivabradine (Corlanor) are subject to prior authorization and a quantity limit (60 tablets/30 days); failure to obtain PA or exceeding QL may result in denial.

    • Ivabradine (Corlanor) — Requirements/Limits = PA, QL (60 tablets/30 days).
    Denial Risk

    PA/QL/SP denial risk for respiratory agents

    Certain inhaled and specialty respiratory agents (e.g., Symbicort, Advair Diskus, pirfenidone/Esbriet) list prior authorization, quantity limits and specialty designation; claims may be denied if PA/QL/SP criteria are not met.

    • Advair Diskus — QL noted; Symbicort — QL (1 inhaler/30 days); Pirfenidone (Esbriet) — PA, QL, SP.
    Denial Risk

    PA required for listed specific products — denial risk

    This portion lists products with PA annotations; prescribers must obtain prior authorization for the specific products shown to avoid denial.

    • Tasimelteon (Hetlioz) and Liraglutide (Saxenda) are examples of PA‑required products in these chunks.
    Denial Risk

    PA triggers for weight‑management/controlled agents — denial risk

    Prior authorization is required for several weight‑management and controlled products (liraglutide/Saxenda, phentermine, Qsymia); dispensing without PA may result in denial.

    • Saxenda (liraglutide) — PA and QL; Phentermine and Qsymia — PA and QL requirements are noted.
    Denial Risk

    Denial risk for quantity‑limit exceedance

    Claims that exceed stated quantity limits (e.g., stimulants, opioids, migraine triptans) may be denied without an override or PA; prescribers should adhere to QL values or request authorization.

    • Concerta — QL 30 or 60 tablets/30 days depending on formulation; oxycodone solutions and other opioid formulations have high‑volume QLs and require compliance.
    Denial Risk

    Eltrombopag — PA/QL/SP denial risk

    Coverage for eltrombopag (Promacta) requires prior authorization and is subject to quantity limits and specialty pharmacy routing; absence of PA may lead to denial.

    • Eltrombopag — Requirements/Limits = PA, QL (30 or 60 tablets/30 days depending on strength), SP.
    Denial Risk

    LA and PA products — additional denial risk if not authorized

    Limited access (LA) and PA‑flagged products (e.g., icatibant, miglustat) have additional authorization steps; failure to meet those steps may result in denial.

    • Icatibant (Firazyr) — Requirements/Limits = LA, PA, QL (6 syringes/30 days), SP.
    • Miglustat (Zavesca) — Requirements/Limits = LA, PA, QL (90 capsules/30 days), SP.
    Denial Risk

    Lidocaine topical products — PA/QL denial risk

    Requests for lidocaine topical products (solution, ointment, patch) are subject to prior authorization and quantity limits; lack of PA or QL documentation could trigger denial at point of sale.

    • Lidocaine solution 4% — PA, QL 150 mL/30 days; Lidocaine oint 5% — PA, QL 100 g/30 days; Lidocaine patch 5% (Lidoderm) — PA, QL 90 patches/30 days.
    Denial Risk

    Topical retinoids — PA required, denial risk

    Some topical retinoids (tazarotene, tretinoin) are noted as requiring prior authorization; claims submitted without PA may be denied.

    • Tazarotene cream/gel and tretinoin cream/gel formulations are listed with PA for certain strengths and forms.
    Denial Risk

    Lenalidomide — PA/QL/SP required; denial risk if not met

    Lenalidomide (Revlimid) entries indicate prior authorization, quantity limits and specialty pharmacy designation; prescribers must obtain PA and comply with specialty distribution to ensure coverage.

    • Lenalidomide caps (various strengths) — Requirements/Limits = PA, QL (30 capsules/30 days or 21 capsules/28 days depending on strength), SP.
    Note

    No provider actions in this segment

    No provider actions are stated in this index listing segment.

    Note

    No explicit provider triggers in this index area

    No explicit authorization or denial criteria are present in these chunks; this area functions as an index and product listing.

    Note

    No provider actions specified in this chunk

    No explicit triggers for prior authorization or denial are present in this chunk of the document.

    Note

    No provider actions in this listing chunk

    No provider actions are stated in this chunk; review product listings for PA/QL/SP flags.

    Quantity Limits (QL) — Examples and Values

    abacavir sulfate soln 20 mg/ml — 960
    Abacavir sulfate oral solution 20 mg/mLQL 960 mls/30 days
    SupportListed as lamivudine and other antivirals with QL entries in same section
    Source noteSee antiviral product QL listings in formulary (abacavir/lamivudine entries)
    abacavir sulfate tab 300 mg — 60
    Abacavir sulfate tablet 300 mgQL 60 tablets/30 days
    ContextListed among antiretroviral tablet QLs in formulary antiviral section
    lamivudine oral soln 10 mg/ml — 960
    Lamivudine oral solution 10 mg/mL (Epivir)QL 960 mls/30 days
    Related formulationsLamivudine tablets have separate QLs (e.g., 60 or 30 tablets/30 days depending on strength)
    YEZTUGO - lenacapavir sodium tab 300 mg — 4
    YEZTUGO — lenacapavir sodium tablet 300 mgQL 4 tablets/365 days (listed as QL 4/year) and SP/ACA annotations
    Related presentationSubcutaneous lenacapavir formulation is listed with SP/ACA flags in same antiviral section
    various antiretroviral tablets (examples) — 30-180
    Antiretroviral tablets (examples)Various tablet QLs shown across products: typical ranges 30–180 tablets per 30 days depending on agent and strength
    ExamplesEmtricitabine, tenofovir, lamivudine tablets listed with QL 30–180 (see antiviral section)
    several oral oncolytics (abiraterone, dasatinib, erlotinib, etc.) — varies (30/60/90/120)
    Selected oral oncolytics (examples)Quantity limits vary by product and strength (examples include 30/60/90/120 tablets or capsules per 30 days as listed)
    Representative agentsAbiraterone, dasatinib, erlotinib, everolimus, imatinib, nilotinib, pazopanib, sorafenib, sunitinib — many have PA, QL, SP designations
    estradiol gel (Estrogel) — 1 pump
    Estradiol gel (Estrogel)QL 1 pump/30 days
    Estradiol TD gel (Divigel)QL 30 packets/30 days
    Estradiol TD gel 1.25 mg (Divigel)QL 37.5 grams/30 days
    Estradiol TD patch (Vivelle-Dot)QL 8 patches/28 days
    estradiol td gel (Divigel) — 30 packets
    Estradiol TD gel (Divigel)QL 30 packets/30 days
    Alternate metricAlso listed as 37.5 grams for certain Divigel strengths
    estradiol td gel 1.25 mg (Divigel) — 37.5 grams
    Divigel 1.25 mg (1.25 mg/g) presentationQL 37.5 grams/30 days
    ContextStrength-specific grams-based QL provided in formulary estrogen section
    estradiol td patch (Vivelle-dot) — 8 patches
    Estradiol TD patch (Vivelle-Dot)QL 8 patches/28 days
    Coverage noteListed under estrogens with QL in formulary estrogen section
    ganirelix (Ganirelix acetate) — 5 syringes
    Ganirelix (Ganirelix acetate)QL 5 syringes/30 days
    SettingListed with SP designations in specialty endocrine/infertility group
    teriparatide (Forteo) — 1 pen
    Teriparatide (Forteo) soln pen-inj 560 mcg/2.24 mLQL 1 pen/28 days; PA and SP noted
    Coverage noteRequires PA and specialty handling per formulary entry
    JYNARQUE (tolvaptan) — 56 tablets
    JYNARQUE (tolvaptan) therapy pack / tabletsQL 56 tablets/28 days (therapy pack); alternate QL entries for JYNARQUE noted with LA/PA/SP
    RelatedOther tolvaptan (Samsca) QLs listed separately (30/60 tablets depending on strength)
    tolvaptan (Samsca) — 30 or 60 tablets depending on strength
    Tolvaptan (Samsca) — generalQL 30 or 60 tablets depending on strength (examples: 30 tablets/365 days or 60 tablets/365 days listed)
    NotesEntries include SP designation and alternate yearly QL metrics
    tolvaptan 30 mg (Samsca) — 30
    Tolvaptan 30 mg (Samsca)QL 30 tablets/365 days (listed as 30/year)
    ContextYear-based QL for certain tolvaptan strengths appears in formulary antiviral/metabolic section
    enalapril oral solution (Epaned) 1 mg/mL — 1200
    Enalapril oral solution (Epaned) 1 mg/mLQL 1200 mLs/30 days; PA required
    Provider actionPA documentation expected when requesting enalapril oral solution beyond QL
    ambrisentan (Letairis) — 30
    Ambrisentan (Letairis)QL 30 tablets/30 days; PA/SP noted
    Use caseListed among PAH agents subject to PA and QL enforcement
    bosentan (Tracleer) 62.5/125 mg — 60
    Bosentan (Tracleer) 62.5/125 mgQL 60 tablets/30 days; PA and SP indicated
    NotesPA/QL and specialty routing apply per formulary oncology/cardiovascular listings
    ivabradine (Corlanor) — 60
    Ivabradine (Corlanor)PA; QL 60 tablets/30 days
    ContextListed with other cardiac agents requiring PA/QL
    sildenafil (Revatio) 20 mg — 90
    Sildenafil (Revatio) 20 mgPA; QL 90 tablets/30 days; SP noted for PAH formulations
    Alternative formulationSildenafil suspension also listed with PA and QL (2 bottles/30 days)
    tadalafil (Adcirca) 20 mg — 60
    Tadalafil (Adcirca) 20 mgPA; QL 60 tablets/30 days; SP noted
    RelatedOther tadalafil strengths (Cialis) have separate QLs (see formulary)
    avanafil (Stendra) — 6
    Avanafil (Stendra)QL 6 tablets/30 days
    CategoryListed under erectile dysfunction agents with per-30-day QL
    sildenafil (Viagra) — 6
    Sildenafil (Viagra)QL 6 tablets/30 days
    NoteOral ED tablet QLs distinct from PAH Revatio QLs
    ivabradine (Corlanor) — 60 (duplicate listing)
    Ivabradine (Corlanor) duplicate listingQL 60 tablets/30 days (duplicate entry in PAH/cardiac section)
    Editorial noteSame QL reiterated in cardiac agent listing
    sildenafil citrate tab (Revatio) — 90
    Sildenafil citrate tablets (Revatio)QL 90 tablets/30 days
    Formulation noteTablet QL shown separately from suspension QL entries
    tadalafil tab (Adcirca) — 60
    Tadalafil tablets (Adcirca)QL 60 tablets/30 days
    ContextPA and SP noted for PAH formulation
    tadalafil 2.5 mg and 5 mg (Cialis) — 30
    Tadalafil 2.5 mg and 5 mg (Cialis)QL 30 tablets/30 days
    Lower-dose daily useQL reflects daily low-dose prescribing for ED/BPH prevention
    tadalafil 10 mg, 20 mg (Cialis); vardenafil — 6
    Tadalafil 10 mg, 20 mg (Cialis) and vardenafilQL 6 tablets/30 days
    On-demand useShort-course QL for on-demand ED dosing
    albuterol inhaler — 2
    Albuterol inhalerQL 2 inhalers/30 days
    Nebulized/albuterol solutionsSeparate QLs may apply to nebulizer solutions; check respiratory section
    fluticasone-salmeterol (Symbicort) — 1
    Fluticasone–salmeterol (Symbicort/Advair)Symbicort QL 1 inhaler/30 days; Advair Diskus QL 60 blisters/30 days
    Respiratory controlsInhaled combination products have inhaler/blister QLs as specified
    pirfenidone (Esbriet) cap/tab — varies (90-180)
    Pirfenidone (Esbriet)PA; QL varies by formulation: 90–180 capsules/tablets/30 days depending on strength/formulation
    Specialty noteListed with SP designation for specialty routing
    esomeprazole packets (Nexium) — 60
    Esomeprazole packets (Nexium)QL 60 packets/30 days
    Suspension/packet documentationPA/QL may require supporting documentation when requested
    sevelamer carbonate/hcl — varies (150-960)
    Sevelamer carbonate / sevelamer HClQL varies by presentation (examples: 150–960 tablets/packets/30 days as listed)
    Formulation dependentPacket and tablet QLs differ by strength and presentation
    oxybutynin solutions — 600
    Oxybutynin solutionsQL 600 mLs/30 days
    Other formulationsTablets/capsules have separate QLs (see genitourinary section)
    progesterone vaginal insert (Endometrin) — 84
    Progesterone vaginal insert (Endometrin)QL 84 suppositories/28 days
    Endometrin listingAlso displayed as QL 84 suppositories in adjacent vaginal products entries
    Endometrin — 84 suppositories
    Endometrin (duplicate)QL 84 suppositories/28 days
    NoteRepeated in vaginal products listing to emphasize QL
    aripiprazole oral solution 1 mg/ml — 900 mls
    Aripiprazole oral solution 1 mg/mLQL 900 mLs/30 days
    Adjunct noteOral solution QL separate from tablet QLs for aripiprazole formulations
    clozapine tabs (various strengths) — 90-270 tablets
    Clozapine tablets (various strengths)QL varies by formulation/strength (90–270 tablets/30 days as listed)
    MonitoringClozapine entries include high QLs for certain ODT/tablet strengths
    eszopiclone — 30 or 90 tablets
    Eszopiclone (Lunesta)QL 30 or 90 tablets/30 days depending on strength/formulation
    Hypnotic controlsFormulation-specific QLs noted in sleep agents section
    eszopiclone — zolpidem — 30-60-90 tablets (varies)
    Zolpidem formulationsQL varies by formulation/strength: 30, 60 or 90 tablets/30 days as specified
    Formulation noteExtended-release and immediate-release strengths differ in QL
    tasimelteon (Hetlioz) 20 mg — 30 capsules
    Tasimelteon (Hetlioz) 20 mgPA; QL 30 capsules/30 days; SP
    Specialty noteDesignated PA and SP in sleep disorder agents listing
    atomoxetine (various strengths) — 30-60 capsules
    Atomoxetine (various strengths)QLs range 30–60 capsules/30 days depending on strength
    Strength-specific10–40 mg caps QL 60/30 days; 60–100 mg caps QL 30/30 days
    liraglutide (Saxenda) — 15 mls
    Liraglutide (Saxenda)PA; QL 15 mLs/30 days (pen-injection solution)
    CoverageWeight-management formulation requires PA and has a per-30-day mL QL
    atomoxetine hcl cap 10-40 mg — 60
    Atomoxetine HCl cap 10–40 mgQL 60 capsules/30 days
    Use noteLower-dose atomoxetine strengths have larger monthly QLs
    lisdexamfetamine (Vyvanse) — 30
    Lisdexamfetamine (Vyvanse)QL 30 capsules/30 days
    ADHD stimulant controlStandard monthly QL for Vyvanse across strengths
    oxycodone hcl soln 5 mg/5ml — 5400
    Oxycodone HCl solution 5 mg/5 mLQL 5400 mLs/30 days
    Opioid controlHigh-volume solution QL listed in opioid analgesic section
    tramadol hcl tab ER 100 mg — 30
    Tramadol HCl ER 100 mgPA; QL 30 tablets/30 days
    ER opioid controlER tramadol formulations require PA and are limited monthly
    eltrombopag (Promacta) — 30 or 60 tablets (varies)
    Eltrombopag (Promacta)PA; QL 30 tablets/30 days or 60 tablets/30 days depending on strength; SP
    Hematologic agent noteStrength-dependent QLs with PA and specialty routing
    enoxaparin prefilled syringes — 30 syringes/90 days
    Enoxaparin prefilled syringes (Lovenox)QL 30 syringes/90 days
    Enoxaparin vialsQL 10 vials/90 days
    enoxaparin vials — 10 vials/90 days
    Enoxaparin vials (Lovenox)QL 10 vials/90 days
    Supply period90-day QL metric shown for vials
    icatibant (Firazyr) — 6 syringes/30 days
    Icatibant (Firazyr)QL 6 syringes/30 days; LA/PA/SP noted
    Acute therapyShort-course syringe QL appropriate for hereditary angioedema therapy
    miglustat (Zavesca) — 90 capsules/30 days
    Miglustat (Zavesca)LA, PA; QL 90 capsules/30 days; SP indicated
    Rare disease agentListed with limited access and specialty routing
    rivaroxaban suspension (Xarelto) — 620 mls/30 days
    Rivaroxaban suspension (Xarelto)QL 620 mLs/30 days
    Suspension metricLiquid formulation QL provided for suspension presentation
    latanoprost (Xalatan) ophthalmic solution — 2.5 mls/30 days
    Latanoprost (Xalatan) ophthalmic solutionQL 2.5 mLs/30 days
    Ophthalmic QLPer-30-day mL QL provided for eye-drop agents
    fluocinolone acetonide cream 0.01% — 120 grams
    Fluocinolone acetonide cream 0.01%QL 120 grams/30 days
    Fluocinolone acetonide oil (body/scalp)QL 118.28 mLs/30 days
    Fluocinonide cream 0.1% (Vanos)QL 240 grams/28 days
    fluocinolone acetonide oil 0.01% (body/scalp) — 118.28 ml
    Fluocinolone acetonide oil 0.01% (body/scalp)QL 118.28 mLs/30 days
    Multiple topical metricsOil/cream/ointment QLs provided per formulation
    fluocinonide cream 0.1% (Vanos) — 240 grams
    Fluocinonide cream 0.1% (Vanos)QL 240 grams/28 days
    Alternate QL periodsSome topical QLs use 28-day windows vs 30-day windows per product
    lidocaine solution 4% — 150 mls
    Lidocaine solution 4%PA; QL 150 mLs/30 days
    Lidocaine ointment 5%PA; QL 100 grams/30 days
    Lidocaine patch 5% (Lidoderm)PA; QL 90 patches/30 days
    lidocaine ointment 5% — 100 grams
    Lidocaine ointment 5%PA; QL 100 grams/30 days
    Topical analgesic controlsPA and QL enforced for certain topical anesthetics
    lidocaine patch 5% (Lidoderm) — 90 patches
    Lidocaine patch 5% (Lidoderm)PA; QL 90 patches/30 days
    Durable patch metricPatch QL specified separately from cream/ointment/solution QLs
    triamcinolone acetonide topical (various) — 454 grams
    Triamcinolone acetonide topical preparationsQL 454 grams/30 days (various forms); some lotion/ointment entries also list 120 mLs/30 days
    Dermatologic QLsMultiple topical corticosteroids use grams/mLs QLs per month as listed
    lenalidomide capsules (selected strengths) — 30 capsules/30 days or 21 capsules/28 days
    Lenalidomide capsules (Revlimid) — selected strengthsPA, SP; QL 30 capsules/30 days or 21 capsules/28 days depending on strength
    Specialty oncology routingLenalidomide requires PA and specialty pharmacy handling per formulary entry

    Specialty Pharmacy and Dispensing Requirements

    Billing Rule

    Dispense SP‑designated products via specialty pharmacy

    Some products are labeled SP indicating specialty pharmacy distribution is required; prescribers must route prescriptions to the specialty channel as designated.

    • SP designation appears on multiple specialty, high‑cost or specialty‑handled agents and often accompanies PA/QL flags.
    Billing Rule

    Specialty pharmacy routing required for SP products

    Products marked SP should be dispensed via specialty pharmacy channels per the formulary; prescribers and pharmacies must follow the specialty routing instructions.

    • Examples: tasimelteon (Hetlioz), liraglutide (Saxenda), lenalidomide and other SP‑flagged agents.

    Step Therapy and Related Flags

    ProductFlags / Notes
    APRETUDE - cabotegravir IM extended‑release suspension 600 mg/3 mLACA, LA, SP — indicated in formulary Requirements/Limits (special access and specialty distribution)
    Atazanavir sulfate capsules (150–300 mg)QL indicated (30–60 capsules/30 days) and PA noted for select strengths
    DESCOVY — emtricitabine/TAF 200/25 mgACA; QL 30 tablets/30 days; PA indicated in listing
    Lenacapavir (YEZTUGO) — tablet 300 mg / subcutaneous formulationACA; QL (4 tablets/365 days for oral); SP designation for specialty handling
    Vancomycin HCl (Vancocin/Firvanq) — oral capsules and solutionListed with Drug Tier = 1; no explicit PA/QL in cited chunks
    Product / ClassSpecialty Routing Implication
    Octreotide acetate injection (various strengths)Requirements/Limits = SP — routed via specialty pharmacy per formulary notes
    Sapropterin (Kuvan) — powder/ tabletsRequirements/Limits = LA, PA, SP — limited access and specialty distribution implied
    Enoxaparin (Lovenox) — prefilled syringes/vialsRequirements/Limits = PA, SP noted in anticoagulant listings; specialty/managed distribution may apply
    Lenacapavir (YEZTUGO) / other antiretroviralsACA/ SP flags present for some ARV products — specialty routing and QL apply
    AgentStep / Specialty Notes
    Tolvaptan (JYNARQUE / Samsca)Listed with QL (30 or 60 tablets/365 days for Samsca; JYNARQUE pack QL noted); SP/LA flags for certain packs — subject to specialty program requirements
    Sapropterin (Kuvan)Requirements/Limits = LA, PA, SP — specialty and prior authorization controls apply
    Sodium phenylbutyrate (Buphenyl)Requirements/Limits = PA, SP — high‑cost endocrine/metabolic agent with specialty handling
    Octreotide injectionRequirements/Limits = SP — specialty agent subject to specialty program routing
    Product / ExampleLA / PA / SP Notes
    Sapropterin (Kuvan) — powder and tablet formsRequirements/Limits = LA, PA, SP — limited access with prior authorization and specialty distribution noted
    Teriparatide (Forteo) — pen‑injector 560 mcg/2.24 mLRequirements/Limits = PA; QL 1 pen/28 days; SP designation for specialty handling
    Miglustat (Zavesca) — 100 mg capsulesRequirements/Limits = LA, PA, QL (90 capsules/30 days), SP — limited access plus PA and specialty routing
    Lenalidomide (Revlimid) — capsules (2.5–25 mg)Requirements/Limits = PA, QL (30 capsules/30 days or 21 capsules/28 days depending on strength), SP — prior authorization and specialty distribution required
    ProductAuthorization / Quantity Limit
    Liraglutide (Saxenda) — solution pen‑injector 18 mg/3 mLRequirements/Limits = PA; QL 15 mL/30 days; no explicit step sequence shown in cited chunks
    Phentermine / Phentermine‑topiramate (Qsymia)Requirements/Limits = PA; QL 30 capsules/30 days — listed as PA‑required weight‑management agents
    Tasimelteon (Hetlioz) 20 mgRequirements/Limits = PA, QL (30 capsules/30 days), SP noted for specialty dispensing where applicable
    ProductStep Therapy Indicator
    Gralise (gabapentin once‑daily) — tablets 300–900 mgRequirements/Limits = QL (30–90 tablets/30 days depending on strength) and ST — step therapy required prior to coverage
    SituationImplication
    Products flagged LA or SP (limited access / specialty)May require stepwise authorization processes, prior authorization, and specialty pharmacy routing per formulary notes
    High‑cost endocrine/metabolic agents (e.g., sapropterin, sodium phenylbutyrate)Marked LA/PA/SP — subject to additional authorization steps and specialty management
    Antineoplastic and hematologic specialty agents (e.g., lenalidomide, eltrombopag)PA, QL, SP commonly applied; specialty distribution and PA are prerequisites for coverage
    ProductSpecialty / Prior Authorization Status
    Lenalidomide (Revlimid) — capsules 2.5, 5, 10, 15, 20, 25 mgRequirements/Limits = PA; QL (30 capsules/30 days or 21 capsules/28 days depending on strength); SP — specialty distribution and prior authorization required

    Definitions and Acronyms

    Background

    Background: This document is an excerpt of the EmblemHealth large-group formulary listing brand and generic drugs covered under the plan. Entries show assigned Drug Tier and, where applicable, utilization controls such as PA, QL, SP, LA, or ACA that govern access and dispensing for listed products.